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Aim. The purpose of this study was to compare the accuracy and clinical implications of three commercial enzyme-linked
immunosorbent assay (ELISA) kits (Eagle Biosciences, Immundiagnostik, andMicroVue) with a validated liquid chromatography-
tandemmass spectrometry (LC-MS/MS) method for the measurement of serum 25(OH)D concentration.Methods. Blood samples
were obtained from 225 healthy individuals who were recruited as subjects from Loughborough University, UK. Plasma samples
were measured for 25(OH)D concentration by means of LC-MS/MS and ELISA kits from Eagle Biosciences, Immundiagnostik,
andMicroVue. Results.The 25(OH)D concentration measured by the Eagle Biosciences, Immundiagnostik, and MicroVue ELISAs
biased −50.9 ± 79.1 nmol/L, −14.2 ± 91.0 nmol/L, and −7.2 ± 18.9 nmol/L (bias ± SD) from the LC-MS/MS method, respectively.
We found that 52% (Eagle Biosciences), 48% (Immundiagnostik), and 38% (MicroVue) of participants were misclassified, and the
results showed the poor agreement (Kappa: −0.201∼0.251) in classification of participants defined as vitamin D sufficiency and
insufficiency between each method and LC-MS/MS. Conclusions.The present study demonstrated that there were negative biases
and considerable misclassification of participants using the cut-off point (50 nmol/L) for vitamin D insufficiency and sufficiency
using the Eagle Biosciences, Immundiagnostik, and MicroVue ELISAs compared with the LC-MS/MS assay.
1. Introduction
Recently, there have been growing demands for measure-
ment of vitamin D status because of the high prevalence
of vitamin D insufficiency and the discovery of vitamin
D nonclassical functions [1, 2]. The high prevalence of
vitamin D insufficiency in the general population worldwide
has been documented in a large number of studies [3].
Moreover, vitamin D insufficiency has also been reported
to be common in athletes especially if exposure to natural
sunlight is limited (e.g., when training in the winter months
or when training mostly indoors) [4]. In addition, it has
been recently recognised that vitamin D plays an important
role in upregulating immunity. Several recent studies have
found a negative association between vitamin D status and
respiratory illness incidence in young and elderly adults [5, 6].
Measurement of plasma 25-hydroxy vitamin D
(25(OH)D) concentration is widely used in clinical practice
and research reports to assess vitamin D status. In humans,
vitamin D can be obtained either from dietary sources or
the epidermal layer of the skin via exposure to sunlight. Two
forms of vitamin D can be obtained from dietary sources:
vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol).
While vitamin D3 is found in food from animal origin,
such as cod-liver oil, salmon, and egg yolk, vitamin D2
is present in some plants and fungi. The endogenously
synthesised vitamin D3 and diet-derived D2 and D3 must
be hydroxylated in the liver into 25(OH)D. 25(OH)D is
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the main storage form, which can be stored in muscles and
adipose tissue and is the major circulating metabolite of
vitamin D, with a plasma half-life of 2-3 weeks. Therefore,
the plasma concentration of 25(OH)D is considered to be the
primary indicator of vitamin D status [7]. Plasma 25(OH)D
values commonly accepted as the reference range [8] are
as follows. In healthy humans, 25(OH)D plasma levels >
100 nmol/L are defined as optimal vitamin D status and levels
from 50 to 100 nmol/L are defined as adequate. Serum levels
of 25(OH)D < 50 nmol/L are proposed to define inadequate
vitamin D status, and values <30 nmol/L represent vitamin
D deficiency.
Plasma 25(OH)D concentration can be measured by
competitive protein binding assay, immunoassay, HPLC,
and LC-MS/MS [1]. The LC-MS/MS method is generally
considered to be the best way for the measurement of serum
25(OH)D levels because it can separate and accurately quan-
titate both 25(OH)D
2
and 25(OH)D
3
[2, 9]; furthermore,
an extraction procedure ensures that both free 25(OH)D
and protein-bound 25(OH)D are quantified. However, as
the LC-MS/MS method requires expensive equipment, large
plasma sample volume, and specialised staff, the commercial
ELISAs are the most popular method for the measurement
of plasma 25(OH)D concentration [1, 2]. Current 25(OH)D
ELISAs employ polyclonal or monoclonal antibodies that
bind specifically to human 25(OH)D. However, the compe-
tition between the 25(OH)D specific antibody and vitamin
D binding protein (VDBP) in plasma samples makes these
assays difficult to control and several of the most commonly
used commercial ELISA kits, such as those manufactured
by DiaSorin, Immunodiagnostic Systems (IDS), and Roche,
have been shown to agree only poorly with LC-MS/MS [1, 2,
10–12]. Given the recent explosion of interest in vitamin D, it
seems to be necessary to establish which of the commercial
ELISAs for plasma/serum 25(OH)D are the most reliable.
The obvious potential advantages of these methods are their
relative ease of use, low cost, and high throughput using small
plasma sample volumes.
The aim of this study was to compare the accuracy
and clinical implications of three commercial ELISA kits
(Eagle Biosciences, Immundiagnostik, and MicroVue) with
LC-MS/MSmethod (carried out in a validated laboratory) for
the measurement of plasma 25(OH)D concentration.
2. Methods
2.1. Participants. A total of 225 healthy individuals were
recruited as subjects from Loughborough University, UK
(latitude 53∘N) during November 2011, in our previous
vitamin D study with the mean age of the study cohort
at recruitment being 21 ± 3 years (mean ± SD). Subjects
were required to complete a comprehensive health-screening
questionnaire prior to starting the study and had not taken
any regular medication or antibiotics in the last 3 months
prior to the study. All subjects were fully informed about
the rationale for the study and of all the experimental
procedures to be undertaken. Subjects provided written
consent to participate in the study, which had earlier received
the approval of Loughborough University Ethical Advisory
Committee. For the visit to the laboratory, subjects arrived
in the morning at 08:30–10:30 following an overnight fast of
approximately 12 hrs, and their body mass and height were
recorded. Information about the studywas given to them, and
they then signed an informed consent form. Subsequently,
a resting venous blood sample (12mL) was obtained by
venipuncture from an antecubital forearm vein into the
vacutainer tube (Becton Dickinson, Oxford, UK) containing
K
3
EDTA. Haematological analysis was immediately carried
out on the EDTA sample (including haemoglobin, haema-
tocrit and total and differential leukocyte counts) using an
automated cell-counter (Ac.T 5diff haematology analyser,
Beckman Coulter, High Wycombe, UK). Subjects had to
have normal haematology to be included in the study. The
remaining EDTA blood was centrifuged for 10min at 1500 g
and 4∘C, and the plasmawas stored at−80∘Cprior to analysis.
Plasma samples were measured for 25(OH)D concentration
bymeans of LC-MS/MS and subsequently by ELISA kits from
Eagle Biosciences (Nashua, NH, USA), Immundiagnostik
(Bensheim and Biomedica, Vienna, Austria), and MicroVue
(Hannover, Germany).
2.2. Liquid Chromatography: Tandem Mass Spectrometry. In
our previous vitamin D study, 225 EDTA plasma samples
were analysed for 25(OH)D
3
, and 25(OH)D
2
with a high
pressure liquid chromatography tandem mass spectrometer
(Waters Acuity, Manchester, UK) after a maximum of 10
months in storage with no previous freeze-thaw cycles as
described previously [13]. Briefly, 25(OH)D
2
, 25(OH)D
3
and
deuterated internal standard were extracted from plasma
samples, following protein precipitation, using isolute C18
solid phase extraction cartridges. Potential interfering com-
pounds were removed by initial elution with 50% methanol
followed by elution of the vitamins using 10% tetrahydrofuran
in acetonitrile. Dried extracts were reconstituted prior to
injection into a high performance liquid chromatography
tandem mass spectrometer in the multiple reaction mode
(MRM).TheMRM transitions (m/z) used were 413.2 > 395.3,
401.1 > 383.3, and 407.5 > 107.2 for 25(OH)D
2
, 25(OH)D
3
andhexadeuterated (OH)D
3
(internal standard), respectively.
Intraassay CVs were <10% across a working range of 2.5–
624 nmol/L for both 25(OH)D
3
and 25(OH)D
2
. Measure-
ments were performed in a laboratory (Norwich University
Hospital, Norwich, UK) meeting the performance target
set by the Vitamin D External Quality Assessment Scheme
(DEQAS) Advisory Panel for 25(OH)D assays.
2.3. Eagle Biosciences. 29 randomly selected EDTA plasma
samples with sufficient volume were assayed for 25(OH)D
concentration using a commercially available ELISA kit
(Eagle Biosciences, Nashua, NH,USA) according to theman-
ufacturer’s instructions. Briefly, the calibrators and patient
samples are diluted with biotin-labelled 25(OH)D and added
to microplate wells coated with monoclonal anti-25(OH)D
antibodies in the first analysis step. An unknown amount
of 25(OH)D in the patient sample and a known amount of
biotin-labelled 25(OH)D compete for the antibody binding
sites in the microplate wells plate during the incubation.
Unbound 25(OH)D is removed bywashing. For the detection
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of bound biotin-labelled 25(OH)D, a second incubation is
performed using peroxidase-labelled streptavidin. In a third
incubation using the peroxidase substrate tetramethylben-
zidine (TMB), the bound peroxidase promotes a colour
reaction. An acidic stopping solution is then added to stop
the reaction. The colour intensity is inversely proportional
to the 25(OH)D concentration. According to information
supplied by the manufacturer, the intraassay CVs were 4.9%
at a 25(OH)D mean concentration of 27.0 nmol/L, 6.9% at a
25(OH)D mean concentration of 61.5 nmol/L and 3.2% at a
25(OH)D mean concentration of 160.3 nmol/L, respectively.
2.4. Immundiagnostik. 29 randomly selected EDTA plasma
samples with sufficient volume were assayed for 25(OH)D
concentration using a commercially available ELISA kit
(Immundiagnostik, Bensheim and Biomedica, Vienna, Aus-
tria) according to the manufacturer’s instructions. Briefly,
in the first incubation step, sample, calibrator, control, the
vitamin D binding protein (VDBP) and the VDBP-Antibody
are added to the solid phase. 25(OH)D present in the sample
then competes with the tracer, coated on the well for the
specific binding site of the binding protein, and the VDBP
antibody is bound to the vitamin binding protein. Hence,
with increasing concentrations of 25(OH)D in the sample, the
amount of binding protein immobilized to the well via the
tracer is reduced. After a washing step to remove unbound
components, the quantification of VDBP is achieved by
incubation with a host specific peroxidase labelled antibody
using TMB as enzyme substrate. An acidic stopping solution
is then added to stop the reaction, and the colour converts
to yellow. The intensity of the yellow colour is indirectly
proportional to the concentration of 25(OH)D in the sample.
The detection limit of the assay was 5.6 nmol/L. According
to the information supplied by the manufacturer, the mean
intraassay and inter-assay CVs of the 25(OH)D assay were
10.7% and 11.8% to 13.2%, respectively.
2.5. MicroVue. 37 randomly selected EDTA plasma samples
with sufficient volume were assayed for 25(OH)D concen-
tration using a commercially available immunoassay kit
(MicroVue, Hannover, Germany) according to the manufac-
turer’s instructions. Briefly, in step 1, standards, controls, and
test specimens are added tomicroplate wells precoated with a
primary monoclonal anti-human 25(OH)D
2
and 25(OH)D
3
antibody. Total 25(OH)D (D
2
and D
3
) in the standards, con-
trols, and samples is dissociated from serum binding proteins
and binds to themonoclonal antibody. In step 2, following the
first wash cycle, a fixed amount of biotinylated 25(OH)D, in
the presence of streptavidin-horseradish peroxidase (HRP),
competes with the unlabelled 25(OH)D
2
and 25(OH)D
3
bound to the monoclonal antibody. At the end of the
assay incubation period, a wash cycle stops the competition
reaction. In step 3, a chromogenic enzyme substrate is added
to each microplate well. The bound HRP conjugate reacts
with the substrate, forming a blue colour. After incubation,
the enzyme reaction is terminated using a stop chemical,
and the colour changes to yellow. The colour intensity of
the reaction mixture is proportional to the concentration
of total 25(OH)D present in the test specimens, standards,
and controls. According to the information supplied by the
manufacturer, the intraassay CVs were 5.7% at a 25(OH)D
mean concentration of 68.5 nmol/L and 2.7% at a 25(OH)D
mean concentration of 107.5 nmol/L, respectively.
2.6. Statistical Analysis. TheWilcoxonmatched-pairs signed-
ranks test was used to test for the differences between
each method and LC-MS/MS. The correlation between each
method and LC-MS/MS was compared using Pearson’s cor-
relation coefficient. Agreement in classification of results
(vitamin D sufficiency: ≥50 nmol/L; vitamin D insufficiency:
<50 nmol/L) between each method and LC-MS/MS was
assessed using Cohen’s kappa (agreement: <0, no; 0–0.4,
poor; 0.4–0.75, fair to good; and >0.75, excellent) [14]. The
simple linear regression and Bland-Altman plots were used
for the comparison of each method and LC-MS/MS. Data
are presented as mean (±SD), and the accepted level of
significance was 𝑃 < 0.05.
3. Results
3.1. LC-MS/MS and Eagle Biosciences. The 25(OH)D concen-
tration measured by the Eagle Biosciences assay was signifi-
cantly lower than the LC-MS/MS assay (Eagle Biosciences:
46.1 ± 29.0 nmol/L, LC-MS/MS: 97.0 ± 77.0 nmol/L; 𝑃 =
0.001) and biased −50.9 ± 79.1 nmol/L (bias ± SD; 95%
limits of agreement: −209.1, 107.3) from the LC-MS/MS assay
(Table 1 and Figure 1(b)).There was no significant correlation
(𝑟 = 0.115, 𝑃 = 0.551) between the LC-MS/MS assay and
the Eagle Biosciences assay (Table 1). Moreover, there was a
considerable misclassification of participants using the cut-
off point for vitamin D insufficiency and sufficiency between
these two assays. The data of our study showed that 52%
(15/29) of participants were misclassified when the results
from the Eagle Biosciences assay were compared with those
from the LC-MS/MS assay. In addition, there were 14% (4/29)
of participants classified as vitamin D insufficient according
to the results from both assays. Cohen’s kappa coefficient was
−0.048 indicating no agreement (Table 2(a)).
3.2. LC-MS/MS and Immundiagnostik. There was no sig-
nificant difference in the 25(OH)D concentration between
the Immundiagnostik assay and the LC-MS/MS assay
(Immundiagnostik: 82.8 ± 45.7 nmol/L, LC-MS/MS: 97.0 ±
77.0 nmol/L; 𝑃 = 0.770) (Table 1). The Immundiagnostik
assay biased −14.2 ± 91.0 nmol/L (bias ± SD; 95% limits
of agreement: −196.3, 167.9) from the LC-MS/MS assay
(Figure 1(d)). However, there was no significantly correlation
between the LC-MS/MS assay and the Immundiagnostik
assay (𝑟 = −0.039, 𝑃 = 0.843) (Table 1). The data of this study
showed that 48% (14/29) of participants were misclassified
when the results from the Immundiagnostik assay were
compared with those from the LC-MS/MS assay. In addition,
there were only 3% (1/29) of participants classified as vitamin
D insufficient according to the results from both assays.
Cohen’s kappa coefficientwas−0.201 indicating no agreement
(Table 2(b)).
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Figure 1: Comparison of the LC-MS/MS method with ELISAs from Eagle Biosciences ((a), (b)), Immundiagnostik ((c), (d)), and MicroVue
((e), (f)) by the simple linear regression ((a), (c), and (e)) and Bland-Altman plots ((b), (d), and (f)).
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Table 1: Comparison of mean (SD) 25(OH)D concentrations (nmol/L) from different 25(OH)D assays.
Sample size for
comparison bloods LC-MS/MS Eagle Biosciences Immundiagnostik MicroVue
Wilcoxon
signed-rank test
Pearson’s
correlation
𝑛 = 29
97.0 ± 77.0 46.1 ± 29.0
𝑃 = .001 𝑃 = .551
𝑛 = 29
97.0 ± 77.0 82.8 ± 45.7
𝑃 = .770 𝑃 = .843
𝑛 = 37
57.1 ± 23.1 50.0 ± 18.1
𝑃 = .023 𝑃 = .001
Table 2: Comparison of the number and percentage of participants
classified as vitamin D sufficient and insufficient from different
25(OH)D assays.
(a)
𝑛 = 29
Eagle Biosciences
<50 nmol/L ≥50 nmol/L
LC-MS/MS
<50 nmol/L 4 (14%) 5 (18%)
≥50 nmol/L 10 (34%) 10 (34%)
Cohen’s kappa −0.048
(b)
𝑛 = 29
Immundiagnostik
<50 nmol/L ≥50 nmol/L
LC-MS/MS
<50 nmol/L 1 (3%) 8 (28%)
≥50 nmol/L 6 (21%) 14 (48%)
Cohen’s kappa −0.201
(c)
𝑛 = 37
MicroVue
<50 nmol/L ≥50 nmol/L
LC-MS/MS
<50 nmol/L 12 (32%) 5 (14%)
≥50 nmol/L 9 (24%) 11 (30%)
Cohen’s kappa 0.251
3.3. LC-MS/MS and MicroVue. The 25(OH)D concentration
measured by theMicroVue assay was significantly lower than
the LC-MS/MS assay (MicroVue: 50.0 ± 18.1 nmol/L; LC-
MS/MS: 57.1 ± 23.1 nmol/L, 𝑃 = 0.023) and biased −7.2 ±
18.9 nmol/L (bias ± SD; 95% limits of agreement: −44.9,
30.6) from the LC-MS/MS assay (Table 1 and Figure 1(f)).
Nevertheless, there was a significant positive correlation
between the LC-MS/MS assay and the MicroVue assay (𝑟 =
0.603, 𝑃 = 0.001) (Table 1). The data of this study showed
that 38% (9/37) of participants were misclassified when the
results from the MicroVue assay were compared with those
from the LC-MS/MS assay. Moreover, there were 32% (12/37)
of participants classified as vitamin D insufficient according
the results from both assays. Cohen’s kappa coefficient was
0.251 indicating poor agreement (Table 2(c)).
4. Discussion
To our knowledge, this is the first report to compare the
accuracy and clinical implications of the Eagle Biosciences,
Immundiagnostik, and MicroVue commercial immunoassay
kits with the LC-MS/MS method for the measurement of
plasma 25(OH)D concentration. The main findings were
that there were negative biases in the Eagle Biosciences,
Immundiagnostik, and MicroVue assays compared with the
LC-MS/MS assay. Furthermore, there was no significant
correlation betweenEagle Biosciences andLC-MS/MS aswell
as Immundiagnostik and LC-MS/MS. Nevertheless, there
was a positive correlation between the MicroVue and LC-
MS/MS assay. In addition, there was a considerable misclas-
sification of participants using the cut-off point for vitamin
D insufficiency and sufficiency between each assay and the
LC-MS/MS assay. The results of the present study showed no
agreement in classification of participants defined as vitamin
D sufficient and insufficient between Eagle Biosciences and
LC-MS/MS as well as Immundiagnostik and LC-MS/MS and
only poor agreement between MicroVue and LC-MS/MS.
The reasons for the negative biases in the Eagle Bio-
sciences, Immundiagnostik, and MicroVue assays compared
with the LC-MS/MS assay are not clear. However, a con-
founding factor for the variable results might be due to the
strong binding of 25(OH)D to VDBP. The serum 25(OH)D
concentration cannot be measured accurately unless it is
released from VDBP and the strong protein binding of
25(OH)D requires the employment of suitable conditions
to release 25(OH)D from VDBP [1, 2]. In the LC-MS/MS
assay of the present study, 25(OH)D
2
and 25(OH)D
3
were
extracted from plasma samples using isolute C18 solid phase
extraction cartridges. Nevertheless, all the immunoassays
that were examined in this study employed monoclonal
25(OH)D antibodies to bind 25(OH)D from VDBP. The
competition between the specific antibody and VDBP in
plasma samples could make these immunoassays difficult
to control and may lead to poor agreement with the LC-
MS/MS assay [10, 15]. Another confounding factor might be
due to the quantitation of plasma 25(OH)D
2
and 25(OH)D
3
.
Because isotope dilution LC-MS/MS methods can simul-
taneously and accurately quantitate both 25(OH)D
2
and
25(OH)D
3
, it can be considered to be the gold standard
method for the measurement of plasma or serum 25(OH)D
levels [1, 2, 9].The present immunoassays cannotmeasure the
concentration of 25(OH)D
2
and 25(OH)D
3
independently.
It has been reported that there was an underestimation
of plasma 25(OH)D
2
concentration in several commercial
immunoassays which resulted in marked variations of the
total plasma 25(OH)D levels [1, 2]. Nevertheless, the results
of the present study showed that there was a positively
correlation between the MicroVue ELISA and LC-MS/MS
methods and had better agreement than the other two
commercial ELISAs that were examined. It might be due to
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the employment of both monoclonal anti-human 25(OH)D
2
and 25(OH)D
3
antibody in the MicroVue assay.
There was a considerable misclassification of participants
using the cut-off point for vitamin D insufficiency and
sufficiency in the Eagle Biosciences, Immundiagnostik, and
MicroVue assays compared with the LC-MS/MS assay. In
healthy humans, plasma 25(OH)D serum levels >100 nmol/L
are defined as optimal vitamin D status, and levels from 50 to
100 nmol/L are defined as adequate. Serum levels of 25(OH)D
<50 nmol/L are proposed to define inadequate vitamin D
status, and values <30 nmol/L represent vitamin D deficiency
[8]. Therefore, the commonly used cut-off point for vitamin
D insufficiency in clinical practice and research reports
is the threshold concentration of 25(OH)D of <50 nmol/L
[11]. On the basis of the present data, we found that 52%,
48%, and 38% of participants were misclassified when the
results from the Eagle Biosciences, Immundiagnostik and
MicroVue assays were compared with those from the LC-
MS/MS assay, respectively. In addition, according to Cohen’s
kappa coefficient from this study (kappa: −0.201∼ 0.251),
the results showed the poor agreement in classification of
participants defined as vitamin D sufficient and insufficient
between each method and LC-MS/MS [14]. Measurement
of plasma 25(OH)D concentration is widely used in clinical
practice and research reports to assess vitamin D status of
participants. Our results indicated that the assessment of
vitamin D status seems to be influenced substantively by the
25(OH)D assay being used. Given the large proportion of
misclassified participants using the present immunoassays,
it is important to discover if there are any more reliable
commercial immunoassays of serum 25(OH)D, which are
suitable for clinicians and researchers.
In conclusion, the present study demonstrated that there
were negative biases and the considerable misclassifica-
tion of participants using the cut-off point for vitamin D
insufficiency and sufficiency using the Eagle Biosciences,
Immundiagnostik, and MicroVue assays compared with the
LC-MS/MS assay. Without using the most reliable 25(OH)D
assays, the assessment of vitamin D status of participants
remains very doubtful.
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